Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Alexion

Bone-building drug which prevents fractures in people with osteoporosis approved for use in UK – here’s how it works

A new anti-osteoporosis drug has just been approved for use in the UK. The drug, called abaloparatide, is licensed for post-menopausal women with osteoporosis and a very high risk of fractures. Abaloparatide’s approval could benefit more than 14,000 women in the UK who are at serious risk of bone fracture.

The Conversation

5 Amazing Stocks You Won’t Ever Regret Buying

5 Amazing Stocks You Won’t Ever Regret Buying

Easing inflation and the Fed’s indication of slowing the pace of interest rate hikes are raising investors’ sentiments. Moreover, the November job report came in better than expected. While uncertainties remain, we think quality stocks Pfizer (PFE), AstraZeneca PLC (AZN), Carrier Global (CARR), J. Jill (JILL), and Lifeway Foods (LWAY)…

AstraZeneca returns to profit on higher drugs revenue

AstraZeneca returns to profit on higher drugs revenue

London (AFP) - British pharmaceuticals giant AstraZeneca on Thursday announced a return to third-quarter profit on increased revenue from sales of its drugs.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Sales of Covid vaccine set to decline as demand wanes, AstraZeneca predicts

The business has already seen a significant drop in the use of its vaccines to Europe.

The Independent UK

AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai

Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris (ravulizumab).

inkl

Read news from The Economist, FT, and more,
with one subscription

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a

AstraZeneca warns on falling Covid treatment sales

AstraZeneca warns on falling Covid treatment sales

London (AFP) - British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes.

Covid vaccine maker AstraZeneca says 2021 profit dives

Covid vaccine maker AstraZeneca says 2021 profit dives

London (AFP) - British Covid vaccine maker AstraZeneca said Thursday that net profit collapsed last year, hit by the vast takeover of US biotech firm Alexion and other charges, despite surging revenues.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

AstraZeneca Plc

Roche Holdings AG

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

231,463 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play